{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=49", "query": { "intervention": "pembrolizumab", "page": 49 }, "page_size": 10 }, "pagination": { "page": 49, "page_size": 10, "total_count": 1847, "total_pages": 185, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=50&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=pembrolizumab&page=48&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T02:26:49.032Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03825510", "title": "Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Nonsmall Cell Lung Cancer", "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Stereotactic Body Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION" ], "sponsor": "Crozer-Keystone Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2017-04-28", "completion_date": "2022-03-08", "has_results": false, "last_update_posted_date": "2023-03-06", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03825510" }, { "nct_id": "NCT06579196", "title": "Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "Trabedersen", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 45, "start_date": "2025-05-12", "completion_date": "2029-02", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT06579196" }, { "nct_id": "NCT03058289", "title": "A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma", "Lymphoma", "Pancreatic Cancer", "Liver Cancer", "Colon Cancer", "Lung Cancer", "Bile Duct Cancer", "Chordoma of Sacrum", "Sarcoma" ], "interventions": [ { "name": "INT230-6", "type": "DRUG" }, { "name": "anti-PD-1 antibody", "type": "BIOLOGICAL" }, { "name": "anti-CTLA-4 antibody", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Intensity Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 111, "start_date": "2017-02-09", "completion_date": "2023-02-22", "has_results": true, "last_update_posted_date": "2025-02-27", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 7, "location_summary": "Los Angeles, California • Newport Beach, California • Baltimore, Maryland + 4 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Worcester", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03058289" }, { "nct_id": "NCT02263508", "title": "Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Melanoma" ], "interventions": [ { "name": "Talimogene Laherparepvec", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "95 Years", "sex": "ALL", "summary": "18 Years to 95 Years" }, "enrollment_count": 713, "start_date": "2014-12-08", "completion_date": "2021-03-11", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Beverly Hills, California + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Duarte", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02263508" }, { "nct_id": "NCT04510597", "title": "Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastatic Clear Cell Renal Cell Carcinoma", "Metastatic Renal Cell Carcinoma", "Stage IV Renal Cell Cancer AJCC v8" ], "interventions": [ { "name": "Cytoreductive Nephrectomy", "type": "PROCEDURE" }, { "name": "Active Comparator", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 364, "start_date": "2021-03-08", "completion_date": "2033-07", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 387, "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Kingman, Arizona + 262 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04510597" }, { "nct_id": "NCT02771197", "title": "Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northside Hospital, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 20, "start_date": "2016-09-28", "completion_date": "2023-07-31", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02771197" }, { "nct_id": "NCT02882282", "title": "Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oral Cavity Carcinoma", "Oral Intraepithelial Neoplasia" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Patient Observation", "type": "OTHER" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2017-06-14", "completion_date": "2025-07-14", "has_results": true, "last_update_posted_date": "2025-10-23", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02882282" }, { "nct_id": "NCT04128423", "title": "Study of AMV564 in Subjects With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced or Metastatic Solid Tumors" ], "interventions": [ { "name": "AMV564", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amphivena Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 65, "start_date": "2019-10-09", "completion_date": "2021-12-31", "has_results": false, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 11, "location_summary": "Los Angeles, California • Orlando, Florida • Tampa, Florida + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT04128423" }, { "nct_id": "NCT07458347", "title": "A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "KRAS-mutant Non-small Cell Lung Cancer (NSCLC)", "KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)", "KRAS-mutant Colorectal Cancer (CRC)", "Other KRAS-mutant Solid Tumors" ], "interventions": [ { "name": "KST-6051", "type": "DRUG" }, { "name": "Gemcitabine/nab-paclitaxel", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "mFOLFOX6", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kestrel Therapeutics, Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 545, "start_date": "2026-04-21", "completion_date": "2029-04", "has_results": false, "last_update_posted_date": "2026-10-15", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 9, "location_summary": "Los Angeles, California • Sarasota, Florida • Tampa, Florida + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT07458347" }, { "nct_id": "NCT03322540", "title": "Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2017-12-15", "completion_date": "2020-11-09", "has_results": true, "last_update_posted_date": "2025-08-22", "last_synced_at": "2026-11-02T02:26:49.032Z", "location_count": 15, "location_summary": "Anaheim, California • Whittier, California • Fort Myers, Florida + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Newnan", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03322540" } ] }